In this Journal Club, Minoli Perera reflects on a 2005 sequencing study by Cohen et al., who discovered two common loss-of-function mutations with large effects on plasma cholesterol levels thanks ...

John Leonard, President and Chief Executive Officer, Intellia Therapeutics: It is. I would say that the patient population that you’ve seen in the Acaramidis study as well as Helios B is pretty ...

NEW YORK, March 10, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Intellia ...

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) investors of an upcoming deadline ...

PORTLAND, US, Mar 10 2025 (IPS) - Country populations worldwide are experiencing the demographic ageing transformation. The relatively young populations experienced during most of the 20th century are ...

Intellia Therapeutics has a 12-month low of $8.30 and a 12-month high of $32.00. The firm has a market cap of $1.07 billion, a PE ratio of -1.90 and a beta of 1.97. Insider Transactions at ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 ...

LOS ANGELES, March 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics ...

Feasibility and Acceptability of Collecting Passive Smartphone Data for Potential Use in Digital Phenotyping Among Family Caregivers and Patients With Advanced Cancer Initial LDCT orders were placed ...

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA ...

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for ...